Skip to main content
To KTH's start page

Publications

The 50 latest publications

[1]
U. Marking et al., "Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in sweden," The Lancet - Infectious diseases, vol. 24, no. 2, pp. e80-e81, 2024.
[3]
M. Dannemeyer et al., "Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors," Protein Expression and Purification, vol. 221, 2024.
[5]
A. Wisniewski et al., "Targeted HER2-positive cancer therapy using ADAPT6 fused to horseradish peroxidase," New Biotechnology, vol. 83, pp. 74-81, 2024.
[6]
J. Scheffel et al., "Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH," Journal of Chromatography A, vol. 1694, pp. 463902, 2023.
[11]
O. Bladh et al., "Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose," The Lancet Microbe, vol. 4, no. 7, pp. 488, 2023.
[12]
U. Marking et al., "7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection," The Lancet - Infectious diseases, vol. 23, no. 2, pp. 150-152, 2023.
[13]
M. Wolf-Watz et al., "Calcium-dependent protein folding in a designed molecular switch," Biophysical Journal, vol. 122, no. 3S1, 2023.
[14]
J. Nilvebrant, S. Hober and S. Kanje, "Ligand and use thereof," us 11820802 (2023-11-21), 2023.
[19]
S. Havervall et al., "Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time," Clinical & Translational Immunology (CTI), vol. 11, no. 4, 2022.
[20]
K. Asplund Högelin et al., "B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients," European Journal of Neurology, vol. 29, no. 11, pp. 3317-3328, 2022.
[22]
S. Appelberg et al., "A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells," EMBO Molecular Medicine, vol. 14, no. 10, 2022.
[23]
S. Havervall et al., "Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection," New England Journal of Medicine, vol. 387, no. 14, pp. 1333-1336, 2022.
[24]
[25]
[27]
[28]
[29]
C. Ekblad et al., "Polypeptides based on a scaffold," us 11505576 (2022-11-22), 2022.
[32]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, pp. 46-52, 2022.
[34]
K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.
[37]
O. Bragina et al., "Phase I Study of Tc-99(m)-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer," Journal of Nuclear Medicine, vol. 62, no. 4, pp. 493-499, 2021.
[38]
J. Dillner et al., "High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers," The Journal of Infectious Diseases, vol. 224, no. 1, pp. 14-20, 2021.
[39]
M. Hedhammar, J. Nilvebrant and S. Hober, "Zbasic : A Purification Tag for Selective Ion-Exchange Recovery," in Protein Downstream Processing : Design, Development, and Application of High and Low-Resolution Methods, : Humana Press, 2021, pp. 149-158.
[40]
J. Scheffel, S. Kanje and S. Hober, "ZCa : A protein A-derived domain with calcium-dependent affinity for mild antibody purification," in Methods in Molecular Biology, NaNth ed. : Humana Press Inc., 2021, pp. 245-249.
[41]
J. Nilvebrant, M. Åstrand and S. Hober, "An orthogonal fusion tag for efficient protein purification," in Methods in Molecular Biology, NaNth ed. : Springer Nature, 2021, pp. 159-166.
[45]
S. Klevebro et al., "Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care," Scandinavian Journal of Public Health, vol. 49, no. 7, pp. 707-712, 2021.
[46]
E. von Witting, S. Hober and S. Kanje, "Affinity-Based Methods for Site-Specific Conjugation of Antibodies," Bioconjugate chemistry, vol. 32, pp. 1515-1524, 2021.
[47]
S. Hassan et al., "SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden," Journal of Internal Medicine, vol. 290, no. 2, pp. 430-436, 2021.
[48]
S. Havervall et al., "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers," Journal of the American Medical Association (JAMA), vol. 325, pp. 2015, 2021.
[49]
K. A. Hogelin et al., "Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 348-348, 2021.
[50]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.